Waiting
Login processing...

Trial ends in Request Full Access Tell Your Colleague About Jove
Journal / Neuroscience / The NeuroStar TMS Device: Conducting the FDA…
JoVE Journal
Neuroscience

This content is Free Access.

JoVE Journal Neuroscience
The NeuroStar TMS Device
Use of Synaptic Zinc Histochemistry to Reveal Different Regions and Laminae in the Developing and Adult Brain
Journal (Neuroscience)
Use of Synaptic Zinc Histochemistry to Reveal Different Regions and Laminae in the Developing and Adult Brain
Effects of Blast-induced Neurotrauma on Pressurized Rodent Middle Cerebral Arteries
Journal (Neuroscience)
Effects of Blast-induced Neurotrauma on Pressurized Rodent Middle Cerebral Arteries
 
Click here for the English version

The NeuroStar TMS Device: Conducting the FDA Approved Protocol for Treatment of Depression

Article DOI: 10.3791/2345-v • 10:30 min • November 12th, 2010
November 12th, 2010 •
1, 2, 2, 1
1Berenson-Allen Center for Noninvasive Brain Stimulation, Beth Israel Deaconess Medical Center, 2Neuronetics, Inc.

Chapters

Summary
Automatic Translation

Please note that all translations are automatically generated.

Click here for the English version.

In this article, we examine the methodology and considerations relevant to the FDA approved depression treatment protocol using the Neuronetics NeuroStar TMS device.

Tags

NeuroStar TMS Device FDA Approved Protocol Treatment Of Depression NeuroStar Transcranial Magnetic Stimulation (TMS) System Class II Medical Device Pulsed Magnetic Fields Electrical Currents Cortex Physiological Changes Functional Brain Changes O'Reardon Et Al. Industry-sponsored Clinical Trial Major Depression Antidepressant Treatment Trial Active TMS Sham TMS Left Dorsolateral Prefrontal Cortex (DLPFC) Medication-free Patients Montgomery-Asberg Depression Scale (MADRS) Hamilton Depression Rating Scale (HAMD) FDA Approval
Read Article

Get cutting-edge science videos from JoVE sent straight to your inbox every month.

Waiting X
Simple Hit Counter